MDMA treatment

The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. The psilocybin batch was purchased by Reset Mind Sciences Ltd., a Western Australian-based...

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More Hawaii: A bill to establish the Therapeutic Psilocybin Working Group, to study psychedelics' medicinal and therapeutic effects, has been approved with recommended amendments. The measure won support from Democratic...

Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc. have entered into an exclusive sales agreement making PharmAla the sole global reseller of Mindset’s current Good Manufacturing Process (cGMP) psilocybin to licensed clinical researchers....

The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing.  Taking place at the University Hospital Basel (UHB), this...

Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing personalized medicine. The study was conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. The company said it...